hVIVO plc (AIM: HVO)

Market Cap	200.71M
Revenue (ttm)	67.21M
Net Income (ttm)	17.45M
Shares Out	680.37M
EPS (ttm)	0.03
PE Ratio	11.72
Forward PE	20.33
Dividend	0.00 (0.68%)
Ex-Dividend Date	Apr 18, 2024

Volume	7,760,670
Open	29.00
Previous Close	28.70
Day's Range	29.00 - 30.45
52-Week Range	16.76 - 32.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2024

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19,...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Yamin Khan
• Employees: 274
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HVO